Top > Search of International Patents > HEMOPOIESIS-ENHANCING AGENT

HEMOPOIESIS-ENHANCING AGENT NEW_EN

Foreign code F190009957
File No. (S2018-0419-N0)
Posted date Oct 25, 2019
Country WIPO
International application number 2019JP007121
International publication number WO 2019163994
Date of international filing Feb 25, 2019
Date of international publication Aug 29, 2019
Priority data
  • P2018-032469 (Feb 26, 2018) JP
Title HEMOPOIESIS-ENHANCING AGENT NEW_EN
Abstract The present invention addresses the problem of providing: a novel hemopoiesis-enhancing agent; and a drug for preventing or treating anemia, particularly intractable anemia, which contains the hemopoiesis-enhancing agent as an active ingredient. The present invention provides a hemopoiesis-enhancing agent which contains an S-adenosylmethionine synthetase inhibitor.
Outline of related art and contending technology BACKGROUND ART
Conventional, such as aplastic anemia and myelodysplastic syndrome refractory anemia such as red blood cells in hematopoietic not directly effect of urging a hematopoietic formulation, chemotherapeutic or immunosuppressive therapy, a high risk of complications such as hematopoietic stem cell transplantation therapy there were. Further, the therapeutic method and the case of resistance, such as by age and there are many cases not adapt the (non-patent document 1 and 2). This is known as hematopoietic promoter formulation to renal anemia erythropoietin a certain effect is observed, an endogenous erythropoietin production already promoting blood disease anemia due to the effect cannot be expected. Therefore, the most effective treatment of the red cell transfusions and one of the cases it is often necessary, due to the long-term treatment with iron overload cost and the problem of organ failure, transfusion dependent anemia disease of the get away from the refractory and the target one.
On the other hand, S- adenosylmethionine synthetase and the MAT, the inhibitor is a cancer therapeutic agent is a candidate of the (non-patent document 3 and 4). However, S- adenosylmethionine synthetase inhibitors, hematopoietic effect is not known at all.
Scope of claims (In Japanese)[請求項1]
 S-アデノシルメチオニン合成酵素阻害物質を含む、造血促進剤。

[請求項2]
 S-アデノシルメチオニン合成酵素がMAT2Aである、請求項1に記載の造血促進剤。

[請求項3]
 S-アデノシルメチオニン合成酵素阻害物質がシクロロイシン、その誘導体、4H-s-トリアゾロ[4,3-a][1,4]ベンゾジアゼピン誘導体及びそれらの薬学的に許容できる塩から選ばれる、請求項1又は2に記載の造血促進剤。

[請求項4]
 S-アデノシルメチオニン合成酵素阻害物質が3-アセチル-11-ケト-β-ボスウェリック酸、その誘導体及びそれらの薬学的に許容できる塩から選ばれる、請求項1又は2に記載の造血促進剤。

[請求項5]
 請求項1~4のいずれか一項に記載の造血促進剤を含む、貧血の予防又は治療のための医薬。

[請求項6]
 造血前駆細胞を、請求項1~4のいずれか一項に記載の造血促進剤存在下で培養する工程を含む、造血細胞の製造方法。

[請求項7]
 造血促進剤の候補物質の存在下又は非存在下でS-アデノシルメチオニン合成酵素活性を測定する工程、及び、
 造血促進剤の候補物質の存在下のS-アデノシルメチオニン合成酵素活性の測定値が、非存在下の測定値よりも低い候補物質を選択する工程、
 を含む、造血促進剤のスクリーニング方法。

[請求項8]
 造血促進剤の評価物質の存在下でS-アデノシルメチオニン合成酵素活性を測定する工程、及び、
 造血促進剤の評価物質の存在下のS-アデノシルメチオニン合成酵素活性の測定値を指標として、造血促進効果を評価する工程、
 を含む、造血促進剤の評価方法。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • TOHOKU UNIVERSITY
  • Inventor
  • IGARASHI, Kazuhiko
  • KATO, Hiroki
  • ISHII, Yusho
  • NGUYEN, Chi Long
  • HARIGAE, Hideo
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close